Half Year 2019 Xvivo Perfusion AB Earnings Call Transcript
Ladies and gentlemen, welcome to XVIVO Perfusion Report Webcast. I'll now hand over to Magnus Nilsson, CEO. Please go ahead.
()-&
Thank you, and welcome to this interim report January to June 2019. My name is Magnus Nilsson, CEO, and on my side here I have Christoffer Rosenblad, the CFO as well.
So let's start on Page #2, please. So the highlights this year -- this half year, I should say, the last quarter has been -- a lot of things happening, positive things happening. We have got the PMA, which was the full day XPS and STEEN Solution in the United States. We got patents approved for the heart preservation solution, both in the U.S. and Europe. We have had -- we can see or note positive results from the clinical safety study with the hearts device at Lund University Hospital with 6 patients with good results presented at the International Society for Heart and Lung Transplantation. We got approval from the Swedish MPA to start a clinical study for heart
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |